Boehringer et al. v. InvaGen (10/25/18 D.NJ) represented generic in ANDA litigation successfully invalidating asserted patents covering Tradjenta® (linagliptin) and Jentadueto® (linagliption and metformin)

Posted on Jul 17, 2019 in